Ariad Pharmaceuticals Inc fka ARIA

[Whosetosay]

More evidence on how and why the medical community views Ponatinib. Iclusig is a powerful drug for those facing difficult choices on risk that must finally take the drug to survive.

Rather than focus on this market for now, Ariad chases other dreams for Ponatinib that invests scarce cash resource into one failed trial after another. OPTIC-2L the latest boondoggle. All the while, with incorrect focus, Ariad has captured a fraction of the patients for whom their label is most appropriate.

We'll see if PP has enough management sense to correct the Ponatinib situation. Focus on the approved label, partnering in combos is the only Ponatinib lot.


'113 and possibly '788 are now the real value drivers.